Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis.

Mina Hassan-ZahraeeZhan YeLi XiElizabeth DushinJulie LeeJacek RomatowskiJaroslaw LeszczyszynSilvio DaneseWilliam J SandbornChristopher BanfieldJeremy D GaleElena PeevaRandy S LongmanCraig L HydeKenneth E Hung

Published in: Journal of Crohn's & colitis (2023)

Blood and microbiome biomarkers stratify endoscopic, histologic, and tissue molecular response to ritlecitinib, which may help guide future precision medicine approaches to UC treatment.

Keyphrases

ulcerative colitis
ultrasound guided
single molecule
current status
combination therapy
bone marrow